Connect with us

COVID-19

Public Health Agency of Canada “not recommending an additional bivalent booster for the general population this spring”

Published

2 years ago

5 minute read

The federal and provincial governments will have to figure out what to do with millions of COVID-19 vaccine boosters now that it appears they’ll go unused.  On Friday, the Public Health Agency of Canada announced through it’s twitter feed that booster shots should now only be considered for Canadians “at high risk of severe illness”.
Those considered at high risk are those over 80 years old, people between 65 and 79 who haven’t contracted COVID-19 yet, residents living in long-term care homes or with other seniors with complex medical needs, and adults 18 and over who are moderately or severely immunocompromised.
The vast majority of Canadians have already been avoiding the booster shots.  Almost 80% of Canadians haven’t taken a booster in the last 6 months.
It’s also been about 6 months since the Public Health Agency of Canada has reported on the likelihood of becoming ill with COVID-19, being hospitalized or dying while vaccinated and boosted. The last report was made public back at the end of September.

 

Below is the statement on the Public Health Agency of Canada website from Friday, March 3:

OVERVIEW

  • On March 3, 2023, the Public Health Agency of Canada (PHAC) released guidance from the National Advisory Committee on Immunization (NACI) on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19. This guidance is based on current evidence, vaccine principles and NACI expert opinion.
  • NACI now recommends that: Starting in the spring of 2023, an additional booster dose may be offered 6 or more months from the last COVID-19 vaccine dose or infection to the following individuals who are at increased risk of severe illness from COVID-19: (Discretionary NACI recommendation)
    • Adults 80 years of age and older
    • Adults 65 to 79 years of age, particularly if they do not have a known history of SARS-CoV-2 infection
    • Adult residents of long-term care homes and other congregate living settings for seniors or those with complex medical care needs
    • Adults 18 years of age and older who are moderately to severely immunocompromised due to an underlying condition or treatment
  • Bivalent Omicron-targeting mRNA COVID-19 vaccines continue to be the preferred booster products.
  • Individuals who have not received previously recommended doses, including a primary series or fall 2022 booster dose, are recommended to receive them now. For more information, please refer to Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023.

QUOTES

“Bivalent booster dose uptake is still relatively low among the populations at risk of severe disease, and we hope to see this improve. Older adults, particularly those over 80 years, consistently have the highest risk of severe disease, especially if they are unvaccinated. We have historically seen patterns of waning protection against severe disease by 6 months after the last dose, particularly in older adults without prior infection. Because of this, as a precautionary measure, NACI is recommending this spring that an additional bivalent booster dose may be offered after 6 months for those at highest risk of severe disease, including older adults and persons who are moderately to severely immunocompromised. There may be a broader program in fall of 2023, depending on COVID-19 epidemiology.”

– Dr. Shelley Deeks, NACI Chair

“It remains important to stay up to date with your COVID-19 vaccines, including recommended booster doses, given the continued circulation of SARS-CoV-2 virus variants in Canada and elsewhere. Booster doses help to build back protection against severe disease that wanes over time after COVID-19 vaccination or infections. Given the current COVID-19 epidemiology, including the relatively stable disease activity we have observed in recent months, and generally high levels of antibodies against COVID-19 from vaccines and/or infection among Canadians, NACI is currently not recommending an additional bivalent booster for the general population this spring. However, individuals at highest risk of getting severely ill from COVID-19, including older adults and individuals considered immunocompromised, may be offered a spring bivalent booster dose. Regardless of risk factors, I encourage anyone who has not yet received their primary series or their fall 2022 bivalent booster to get these vaccinations now to reduce their risk of severe outcomes of COVID-19, including hospitalization.”

– Dr. Theresa Tam, Chief Public Health Officer

 

Related Topics:

After 15 years as a TV reporter with Global and CBC and as news director of RDTV in Red Deer, Duane set out on his own 2008 as a visual storyteller. During this period, he became fascinated with a burgeoning online world and how it could better serve local communities. This fascination led to Todayville, launched in 2016.

Follow Author

More from this author
Duane Rolheiser / 2 days ago

Carney Wins: What now Alberta?

2025 Federal Election / 4 days ago

Polls say Canadians will give Trump what he wants, a Carney victory.

Also Interesting / 7 days ago

If You Frequently Travel, A Second Phone Number Can Be A Cost Effective Solution

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on May 1, 2025

By

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

COVID-19

Canada’s health department warns COVID vaccine injury payouts to exceed $75 million budget

Published on April 30, 2025

By

Fr0m LifeSiteNews

By Clare Marie Merkowsky

A Department of Health memo warns that Canada’s Vaccine Injury Support Program will exceed its $75 million budget due to high demand, with $16 million already paid out.

COVID vaccine injury payments are expected to go over budget, according to a Canadian Department of Health memo.

According to information published April 28 by Blacklock’s Reporter, the Department of Health will exceed their projected payouts for COVID vaccine injuries, despite already spending $16 million on compensating those harmed by the once-mandated experimental shots.

“A total $75 million in funding has been earmarked for the first five years of the program and $9 million on an ongoing basis,” the December memo read. “However the overall cost of the program is dependent on the volume of claims and compensation awarded over time, and that the demand remains at very high levels.”

“The purpose of this funding is to ensure people in Canada who experience a serious and permanent injury as a result of receiving a Health Canada authorized vaccine administered in Canada on or after December 8, 2020 have access to a fair and timely financial support mechanism,” it continued.

Canada’s Vaccine Injury Support Program (VISP) was launched in December 2020 after the Canadian government gave vaccine makers a shield from liability regarding COVID-19 jab-related injuries.

While Parliament originally budgeted $75 million, thousands of Canadians have filed claims after received the so-called “safe and effective” COVID shots. Of the 3,060 claims received to date, only 219 had been approved so far, with payouts totaling over $16 million.

Since the start of the COVID crisis, official data shows that the virus has been listed as the cause of death for less than 20 kids in Canada under age 15. This is out of six million children in the age group.

The COVID jabs approved in Canada have also been associated with severe side effects such as blood clots, rashes, miscarriages, and even heart attacks in young, healthy men.

Additionally, a recent study done by researchers with Canada-based Correlation Research in the Public Interest showed that 17 countries have found a “definite causal link” between peaks in all-cause mortality and the fast rollouts of the COVID shots as well as boosters.

Interestingly, while the Department of Health has spent $16 million on injury payouts, the Liberal government spent $54 million COVID propaganda promoting the vaccine to young Canadians.

The Public Health Agency of Canada especially targeted young Canadians ages 18-24 because they “may play down the seriousness of the situation.”

The campaign took place despite the fact that the Liberal government knew about COVID vaccine injuries, according to a secret memo.

Continue Reading

Trending

X